

Drug: **HEPARIN SODIUM**
25,000 units in 500 ml D₅W (50 units/ml)

Class: Anticoagulant

ED Use Only

Indication: Treatment of venous thromboembolic disorders.

Suggested Regimen:	Initial dose	Maintenance dose
	50 to 100 units/kg	12 to 25 units/kg/hr

Monitor: aPTT (at baseline, and routinely to guide subsequent dosing regimens), signs of thrombus extension and pulmonary embolism, platelet count, hemoglobin, hematocrit, and signs of bleeding.

Comments: Stable at room temperature for 24 hours.

BOLUS

Wt (lbs)	110	121	132	143	154	165	176	187	198	209	220	231	242
Wt (kg)	50	55	60	65	70	75	80	85	90	95	100	105	110
Bolus units/kg	Bolus Dose in units												
20	1000	1100	1200	1300	1400	1500	1600	1700	1800	1900	2000	2100	2200
50	2500	2750	3000	3250	3500	3750	4000	4250	4500	4750	5000	5000	5000
60	3000	3300	3600	3900	4000	4000	4000	4000	4000	4000	4000	4000	4000
80	4000	4400	4800	5200	5600	6000	6400	6800	7000	7000	7000	7000	7000

BOLUS

INFUSION

Wt (lbs)	110	121	132	143	154	165	176	187	198	209	220	231	242
Wt (kg)	50	55	60	65	70	75	80	85	90	95	100	105	110
Dose units/kg/hr	Infusion Rate in ml/hr												
12	12	13.2	14.4	15.6	16.8	18	19.2	20.4	21.6	22.8	24	25.2	26.4
13	13	14.3	15.6	16.9	18.2	19.5	20.8	22.1	23.4	24.7	26	27.3	28.6
14	14	15.4	16.8	18.2	19.6	21	22.4	23.8	25.2	26.6	28	29.4	30.8
15	15	16.5	18	19.5	21	22.5	24	25.5	27	28.5	30	31.5	33
16	16	17.6	19.2	20.8	22.4	24	25.6	27.2	28.8	30.4	32	33.6	35.2
17	17	18.7	20.4	22.1	23.8	25.5	27.2	28.9	30.6	32.3	34	35.7	37.4
18	18	19.8	21.6	23.4	25.2	27	28.8	30.6	32.4	34.2	36	37.8	39.6
19	19	20.9	22.8	24.7	26.6	28.5	30.4	32.3	34.2	36.1	38	39.9	41.8
20	20	22	24	26	28	30	32	34	36	38	40	42	44
21	21	23.1	25.2	27.3	29.4	31.5	33.6	35.7	37.8	39.9	42	44.1	46.2
22	22	24.2	26.4	28.6	30.8	33	35.2	37.4	39.6	41.8	44	46.2	48.4
23	23	25.3	27.6	29.9	32.2	34.5	36.8	39.1	41.4	43.7	46	48.3	50.6
24	24	26.4	28.8	31.2	33.6	36	38.4	40.8	43.2	45.6	48	50.4	52.8
25	25	27.5	30	32.5	35	37.5	40	42.5	45	47.5	50	52.5	55

INFUSION

These guidelines serve to give dosage ranges and rates of administration. All clinicians are expected to be thoroughly familiar with the drugs mentioned herein.